China NMPA Grants Conditional Approval to Atled for Previously Treated FGFR2-Positive Advanced Intrahepatic Cholangiocarcinoma – HUTCHMED
HUTCHMED (China) announces that the New Drug Application (NDA) for fanregratinib (HMPL-453), a novel, selective, oral inhibitor targeting FGFR 1/2/3, has been granted conditional approval by the China… read more.





